
Apr. 02, 2020 - Demo of the new COVID-19 dedicated protocol
This protocol incudes many clinical key points, particularly about screening, analysis of the pathological stages as well as clinical evolutions.
Watch the replay >
Jun. 26, 2019 - PI-RADS, what's new!? - New elements to improve detection, localization, characterization and risk stratification
During this webinar we will discuss the new features of this standard in the image data acquisition, the interpretation criteria and the role of the biparametric MRI.
Watch the replay >
Press releases

May 17, 2022 - Intrasense launches its AI Hub in partnership with Milvue
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces, in partnership with the company Milvue, the first integration of a solution within its Hub dedicated to artificial intelligence. The AI Hub enables the simple and ergonomic integration of artificial intelligence algorithms and their orchestration within clinical applications to better meet the
needs of users. LEARN MORE >
See also
Previous
press release >
Apr. 20, 2022 - Availability of the 2021 annual financial report
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, announces today the publication of its Annual Financial Report for the year ended December 31, 2021. This Annual Financial Report was approved by the Board of Directors on April 19, 2022. LEARN MORE >
See also
Previous
press release >
Apr. 5, 2022 - TeleDiag chooses Intrasense by signing a commercial contract for teleradiology
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, and TeleDiag, a leading player in teleradiology in France entered into a partnership for the deployment of the Myrian® platform to strengthen clinical efficiency and the management of cancer patients. Learn more >
See also
Previous
press release >
Mar.10, 2022 - Intrasense 2021 results: record business growth
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian®, is today publishing audited 2021 consolidated IFRS financial statements for the Group. Learn more >
See also
Previous
press release >
1st Feb, 2022 - Intrasense and Forcomed sign a five-year strategic partnership agreement
Intrasense and Forcomed, a leading provider of continuing medical education, have entered into a five-year partnership to enable radiologists and radiology technicians to use Myrian® during a new training module on breast imagin. Learn more >
See also
Previous
press release >
Jan 24, 2022 - Intrasense: ambitions and publication calendar for 2022
Intrasense hereby sets out its ambitions, development
plan and financial publication timetable for 2022. Learn more >
See also
Previous
press release >
Jan 18, 2022 - Half year report of Intrasense’s liquidity contract signed with
TSAF –Tradition Securities And Futures
Intrasense announces the publication of its half year
liquidity contract signed with TSAF – Tradition Securities And Futures. Learn more >
See also
Previous
press release >
Oct 05, 2021 - New product line in oncology: a milestone passed with the signature of a partnership between Intrasense and I-SERIS
Intrasense and the medical imaging and radiology group I-SERIS, which includes the clinics of Clémentville (Montpellier), Clermont l'Hérault and the scanner center of the Pasteur clinic in Pézenas, announce the signing of an agreement for the development of the new oncology solution Myra. Learn more >
See also
Previous
press release >
Sep 22, 2021 - HY 2021 Consolidated Results Intrasense Group
Intrasense announces its 2021 consolidated IFRS half-year results at Group level as of June 30, 2021. Learn more >
See also
Previous
press release >
Sep 14, 2021 - Intrasense participates in the SIFEM 2021 congress from September 17 to 19
Intrasense is pleased to announce its participation in the congress of the Société d'Imagerie de la Femme, in Ajaccio from September 17 to 19. Learn more >
See also
Previous
press release >
Sep 07, 2021 - Intrasense provides an update on its development strategy and growth prospects
Intrasense provides an update on its development strategy following its successful capital increase in June 2021. Learn more >
See also
Previous
press release >
Jun 22, 2021 - Intrasense: successful Rights Issue with €4.9 million raised
Intrasense today announced the success of its capital increase through the issuance of new shares (“New Shares”) with shareholders’ preferential subscription rights, for which subscriptions took place between May 28 and June 15, 2021 (the “Rights Issue”). Learn more >
See also
Previous
press release >
May 24, 2021 - Intrasense launches a Rights Issue
Intrasense launch a capital increase through the issuance of new shares with shareholders’ preferential subscription rights. Learn more >
See also
Previous
press release >
Apr. 30, 2021 - Intrasense announces the publication of the annual financial report
Intrasense today announces the publication of its annual financial report for the financial year ended on December 31, 2020. Learn more >
See also
Previous
press release >
Apr. 08, 2021 - Intrasense announces the referencing of its Myrian® platform with Vidi, first cooperative network of medical imaging groups in France
Intrasense and Vidi, the leading cooperative network of medical imaging groups in France, signed an agreement on January 30th, 2021 to reference Myrian® solutions. Learn more >
See also
Previous
press release >
Apr. 01, 2021 - New Myrian platform launch, enriched with many new clinical features dedicated to stroke, breast cancer and cardiovascular pathologies
Intrasense is pleased to present the new version 2.9, with a focus on new clinical features. Learn more >
See also
Previous
press release >
Mar. 23, 2021 - Intrasense Group consolidated 2020 annual results
Intrasense announces its 2020 IFRS Group consolidated annual results. Learn more >
See also
Previous
press release >
Fev. 11, 2021 - Intrasense and MeVis sign a strategic partnership
Intrasense and MeVis Medical Solutions AG specialized in
the development of clinical applications integrating artificial intelligence, announce a global partnership in the field of lung diseases. Learn more >
See also
Previous
press release >
Jan. 29, 2021 - Half year report of Intrasense’s liquidity contract signed with TSAF – Tradition Securities And Futures
Intrasense announces the publication of its half year liquidity contract signed with TSAF – Tradition Securities And Futures. Learn more >
See also
Previous
press release >
Jan. 13, 2021 - New Group Chief Business Officer
Intrasense strengthens its management team with the appointment of Khalil Filali as Group Chief Business Officer. Learn more >
See also
Previous
press release >
Nov. 12, 2020 - New Group Chief Financial Officer
Intrasense announces the appointment of Lionel Seltz as Group Chief Financial Officer. Financial expertise and international background in structuring growing companies to meet the new corporate development requirements. Learn more >
See also
Previous
press release >
Nov. 04, 2020 - Myrian 2.8 launch, new clinical applications and workflow efficiency
Intrasense is pleased to present the new version 2.8 of its visualization platform with many new features, from clinical applications to improved workflow. Learn more >
See also
Previous
press release >
Oct. 08, 2020 - Partial renewal and strengthening of the board of directors
Intrasense announces following a Board meeting on October 8th, 2020, a partial renewal and strengthening of its composition. Michèle Lesieur is coopted as administrator and appointed Chairman of the Board. Anne Larpin is coopted as administrator of the company. The ratification of these cooptations will be submitted to the next ordinary general meeting. Learn more >
See also
Previous
press release >
Sep. 30, 2020 - HY 2020 Consolidated Results Intrasense Group
Intrasense announces its 2020 consolidated IFRS half-year results at Group level as of June 30, 2020. Learn more >
See also
Previous
press release >
Apr. 21, 2020 - CE marking for the CT protocol dedicated to COVID-19
Intrasense announces that the scanner reading protocol dedicated to COVID-19 has obtained its CE marking as a world premiere. Learn more >
See also
Previous
press release >
Apr. 16, 2020 - New version of the COVID-19 protocol
Intrasense continues its involvement in the fight against COVID-19 and announces the availability on Friday April 17th, 2020 of a second version of its scanner reading protocol dedicated to the epidemic. Learn more >
See also
Previous
press release >
Apr. 02, 2020 - Intrasense and Compagnie de Télémédecine join forces in the fight against COVID-19
Intrasense combines its technological expertise with the clinical expertise of the Compagnie de Télémédecine (CTM Groupe) by deploying to all of the group's radiotherapy specialists the new scanner reading protocol dedicated to COVID-19. Learn more >
See also
Previous
press release >
Mar. 30, 2020 - Availability of a new COVID-19 dedicated protocol
The company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19. Learn more >
See also
Previous
press release >
Feb. 10, 2020 - Profitability meeting with 2019 annual results
Intrasense™ announces its 2019 annual results. Learn more >
See also
Previous
press release >
Dec. 19, 2019 - Intrasense™ announces the end of the BCS financing contract
Intrasense™ announces the end of the BCS (Bond Convertible into Shares) financing contract concluded with the Luxembourgish fund European High Growth Opportunities Securitization Fund (EHGO). Learn more >
See also
Previous
press release >
Nov. 19, 2019 - Intrasense™ showcases innovative solutions at RSNA 2019
Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.Learn more >
See also
Previous
press release >
Sep. 30, 2019 - Intrasense™ presents its innovations at JFR 2019 show
All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.Learn more >
See also
Previous
press release >
Sep. 24, 2019 - The new version of Myrian® 2.7 unveiled, many clinical innovations
This new version of Myrian® brings many clinical innovations and a new application.Learn more >
See also
Previous
press release >
Jul. 11, 2019 - 2019 Half -Year Results: strong growth in all financial indicators and convertible bonds contract suspension maintained
Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.Learn more >
See also
Previous
press release >
Jun. 03, 2019 - Myrian® XP-Mammo has been CE marked
Myrian® XP-Mammo, can now be commercialized on the European market.Learn more >
See also
Previous
press release >
Apr. 29, 2019 - Intrasense™ and Radboudumc sign a multiyear partnership, deploying Myrian® XP-Prostate application as a worldwide reference
Myrian® XP Prostate, the new reference tool for worldwide prostate experts.Learn more >
See also
Previous
press release >
Apr. 24, 2019 - Braincarta choose Myrian® to industrialize its application
Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.Learn more >
See also
Previous
press release >
Feb. 20, 2019 - Intrasense and 12 Sigma unveil their innovative artificial intelligence solutions at the ECR 2019 congress
Presentation of 3 innovative products based on Myrian® technology Learn more >
See also
Previous
press release >
Feb. 05, 2019 - Intrasense 2018 annual results bear first fruits of its new strategy
Strong growth, reaching operating balance.
Learn more >
Jan. 28, 2019 - Suspension of financing contract of bonds convertible into shares issuance
suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.
Learn more >
Congresses

Talking about Myrian®
Latest news
Aug. 30, 2018 - Myrian quoted in Nature: article about liver fibrosis >
Scientific publications
Read scientific papers >
Success stories
Read 4 success stories >
